XML 28 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCK-BASED COMPENSATION - Restricted And Unrestricted Stock and Performance Share Units (Details) (USD $)
In Millions, except Share data in Thousands, unless otherwise specified
9 Months Ended
Sep. 28, 2012
Share-based Compensation by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Non-vested at beginning of period, shares 1,266
Granted, shares 614
Vested, shares (362)
Forfeited, shares (98)
Non-vested at the end of the period, shares 1,420
Share-based Compensation by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]  
Non-vested at beginning of period, price $ 13.92 [1]
Granted, price $ 16.84 [1]
Vested, price $ 13.81 [1]
Forfeited, price $ 13.80 [1]
Non-vested at end of the period, price $ 15.21 [1]
Restricted stock
 
Share-based Compensation by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]  
Total unrecognized stock-based compensation expense $ 7.5
Unrecognized stock-based compensation expense for the period identified 6.7
Unrecognized stock-based compensation expense for the period identified, period 1 year 7 months 6 days
Performance shares
 
Share-based Compensation by Share-based Payment Award [Line Items]  
Vesting period 3 years
Share-based Compensation by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]  
Total unrecognized stock-based compensation expense 7.6
Unrecognized stock-based compensation expense for the period identified $ 3.4
Unrecognized stock-based compensation expense for the period identified, period 2 years 1 month 6 days
Minimum | Restricted stock
 
Share-based Compensation by Share-based Payment Award [Line Items]  
Vesting period 3 years
Maximum | Restricted stock
 
Share-based Compensation by Share-based Payment Award [Line Items]  
Vesting period 4 years
[1] Weighted average market price on grant-date.